A5024411516- Bone health and osteoporosis research
- Bone health and treatments
- Hip and Femur Fractures
- Bone Metabolism and Diseases
- Cardiac, Anesthesia and Surgical Outcomes
- Orthopaedic implants and arthroplasty
- Total Knee Arthroplasty Outcomes
- Bone fractures and treatments
- Orthopedic Infections and Treatments
- Bone and Joint Diseases
- Hormonal Regulation and Hypertension
- Heart Failure Treatment and Management
- Lymphoma Diagnosis and Treatment
- Cancer and Skin Lesions
- Nutrition and Health in Aging
- Respiratory and Cough-Related Research
- Medical Imaging and Pathology Studies
- Cancer Diagnosis and Treatment
- Obesity, Physical Activity, Diet
- Estrogen and related hormone effects
- Nausea and vomiting management
- Knee injuries and reconstruction techniques
- Folate and B Vitamins Research
- Digestive system and related health
- Potassium and Related Disorders
University of South Florida
2025
Princess Margaret Hospital
2008-2023
University of Otago
2012-2023
Rata Foundation
2005-2021
Canterbury District Health Board
2011-2021
University of Toronto
2019
Burwood Hospital
2019
Christchurch Hospital
1982-2018
Princess Margaret Cancer Centre
1991-2012
Saint Barnabas Medical Center
2003
ABSTRACT Denosumab reduces bone resorption and vertebral nonvertebral fracture risk. discontinuation increases turnover markers 3 months after a scheduled dose is omitted, reaching above-baseline levels by 6 months, decreases mineral density (BMD) to baseline 12 months. We analyzed the risk of new or worsening fractures, especially multiple in participants who discontinued denosumab during FREEDOM study its Extension. Participants received ≥2 doses placebo Q6M, treatment, stayed ≥7 last...
Odanacatib (ODN) is a selective inhibitor of the collagenase cathepsin K that highly expressed by osteoclasts. In this 2-year, phase 2, dose-ranging trial, postmenopausal women with bone mineral density (BMD) T-scores -2.0 to -3.5 at spine or hip were randomized weekly placebo ODN 3, 10, 25, 50 mg plus vitamin D(3) and calcium. Prespecified trial-extensions continued through 5 years. year all re-randomized placebo. For years 4 5, who received 3 in 1 2 mg; others treatments. Endpoints...
Abstract Osteoporosis is a chronic disease and requires long-term treatment with pharmacologic therapy to ensure sustained antifracture benefit. Denosumab reduced the risk for new vertebral, nonvertebral, hip fractures over 36 months in Fracture Reduction Evaluation of Every 6 Months (FREEDOM) trial. Whereas discontinuation denosumab has been associated transient increases bone remodeling declines mineral density (BMD), effect on fracture during cessation not as well characterized. To...
The effect of 60-min constant iv infusions αhuman atrial natriuretic peptide (αhANP; 200 μg), sufficient to increasethe steady state venous plasma αhANP concentration levels found inpatients with some circulatory disorders, was studied in six normal men equilibrated on a high sodium diet (200 mmol daily) and again when low intake (10 daily). In each instance, the responsestoαhANP were compared those control given preceding day. mean immunoreactive ANP during 320 pmol/liter same both diets....
Context: Patients who sustain an acute spinal cord injury (SCI) experience rapid dramatic reductions in bone mineral density (BMD), especially marked sublesional areas and sometimes leading to hypercalcemia hypercalciuria, as well increased fracture risk. Objective: In this prospective, double-blind, randomized, placebo-controlled study, we evaluated the hypothesis that oral alendronate administration would preserve BMD when administered soon after SCI. Intervention: Thirty-one patients with...
Background There is a medical need for therapies that improve hip fracture healing. Teriparatide (Forteo®/ Forsteo®, recombinant human parathyroid hormone) bone anabolic drug approved treatment of osteoporosis and glucocorticoid-induced in men postmenopausal women at high risk. Preclinical preliminary clinical data also suggest teriparatide may enhance Questions/purposes We wished to test the hypotheses with versus placebo would femoral neck healing after internal fixation as measured by (1)...
Guidelines for doctors managing osteoporosis in the Asia-Pacific region vary widely. We compared 18 guidelines similarities and differences five key areas. then used a structured consensus process to develop clinical standards of care diagnosis management improving quality care. Minimum assessment are needed (AP) inform practice (CPGs) improve present framework these describe its development. conducted comparative analysis existing CPGs AP using "5IQ" model (identification, investigation,...
We studied the effect on bone mass of alendronate treatment for 5 yr and its withdrawal. Four hundred forty-seven postmenopausal women with normal entered a 3-yr randomized trial followed by 2-yr open label extension. Three eleven completed first 3 yr, 263 consented to continue are reporting data from groups using dose currently approved osteoporosis prevention (5 mg) or group in which was withdrawn: 52 received (group I), 56 placebo 2 II), (20 off therapy III). In I, increased mineral...
Objective : To measure the prevalence of low serum vitamin B12, folate, and red cell folate levels their relationship with other nutritional indices. Design Prospective survey elderly subjects using radioisotope dilution assays. Setting Primary care medical center, Christchurch, New Zealand. Patients 257 (age 65 years over), residing in own homes or residential homes, were randomly selected. Of these, 204 (79%) participated. The study population was comparable to Main Outcome Measures...
Ten patients with low grade non-Hodgkin9s lymphoma (seven follicular small cleaved and three lymphocytic) were treated 1 microgram oral alfacalcidol (1 alpha-hydroxycholecalciferol) daily. Of the seven lymphomas of subtype, one achieved complete partial remission, whereas none lymphocytic responded. In 10 patients, 1,25(OH)2D3 receptors measured in tissue from lymph nodes, a positive correlation between presence amount receptor response to was found. These preliminary data suggest that has...
Abstract Background Adults with certain underlying chronic medical conditions are at increased risk of pneumococcal disease (PD). V116 is an investigational, 21-valent, adult-specific conjugate vaccine (PCV) containing the most prevalent serotypes (STs) associated PD in adults from regions established pediatric vaccination programs. The Phase 3 STRIDE-8 study (NCT05696080) evaluated safety and tolerability 18–64 years age PD. Immunogenicity was compared sequential administration 15-valent...
Upper limb fractures (including wrist, forearm, and humerus) represent a significant burden among postmenopausal women with osteoporosis. Up to 7 years of treatment denosumab resulted in an increase bone mineral density decrease upper sites. (wrist, are osteoporosis, associated morbidity mortality. Denosumab, monoclonal antibody against RANK ligand, increases (BMD) decreases vertebral, nonvertebral, hip fractures. Here, we evaluated the long-term effect on fracture risk BMD. In FREEDOM...
Introduction Paget’s disease of bone (PDB) is characterised by increased and disorganised remodelling affecting one or more skeletal sites. Complications include pain, deformity, deafness pathological fractures. Mutations in sequestosome-1 ( SQSTM1 ) are strongly associated with the development PDB. Bisphosphonate therapy can improve pain PDB, but there no evidence that treatment alters natural history PDB prevents complications. The Zoledronate Prevention trial (ZiPP) will determine if...
Osteoporosis is a complex multi-factorial disease where environment, diet and genetics play role in determining susceptibility. Patients with existing vertebral fracture have heightened risk of further recurrent fracture. The efficacy new osteoporosis therapies often compared to calcium supplementation. 1,25-dihydroxyvitamin D3 (calcitriol) acts through the vitamin D receptor (VDR) effective at reducing risk. Because VDR controls metabolism, we hypothesized that genetic variation locus may...
Paget's disease of bone (PDB) frequently presents at an advanced stage with irreversible skeletal damage. Clinical outcomes might be improved by earlier diagnosis and prophylactic treatment.